MEA and impedance measurements using the CardioExcyte 96 system

Ncardia's expertise in MEA assays enables detailed electrophysiological detection of potential test compounds, in a broad throughput range. The CardioExcyte 96 system (Nanion Technologies) simultaneously measures cardiomyocyte contractility and electrophysiology, with which we can provide real-time analysis, enabling short (seconds) to long (days) term measurements of the effects of different compounds on cell behavior.

Case studies assessed the effects of cardioactive compounds on the electrophysiology and impedance of Pluricyte Cardiomyocytes using the CardioExcyte 96 system. Expected pharmacological responses were found in a reproducible manner.

Read the full application note

Application note

Cardiac safety assessment using hiPSC-derived cardiomyocytes with the CardioExcyte 96 system

For this application note, we combined impedance and EFP assays with the CardioExcyte system, and measured them in a non-invasive, label-free manner. The recordings are made from cells within a network thus providing a physiologically relevant environment for measuring drug-induced changes in contractile parameters.

Pluricyte Cardiomyocytes were grown on the NSP-96 plates of the CardioExcyte 96. The cardiomyocytes formed a monolayer and started to beat synchronously, at which point they were used for pharmacological experiments. Effects of nifedipine and dofetilide on the impedance and EFP signals were measured.

The figure below shows the pharmacological response of cardiomyocytes to nifedipine, an L-type calcium channel blocker which causes QT shortening in isolated heart. In impedance mode nifedipine caused a concentration-dependent decrease in amplitude and pulsewidth 20 and an increase in beat rate. Nifedipine had no effect on beat regularity. In EFP mode, nifedipine caused a decrease in field potential duration (FPD) and an increase in beat rate.

Pharmacological response of Pluricyte Cardiomyocytes to nifedipine


This application note shows how we assess the effects of a set of cardio-active compounds on Pluricyte Cardiomyocytes’ electrophysiology by extracellular field potential and impedance, using the CardioExcyte 96.

Through our >10 years of expertise, our MEA assay services can support your Drug Discovery projects, providing you with detailed analyses of either patient derived or genetically modified iPSC models, to study your required disease phenotype and its response to compounds. Results are highly relevant for studying cardiac safety or efficacy profile of compounds through several stages of your drug development projects.

Want to discuss what we can do for you? Please leave your details in the form below and we will get back to you as soon as possible.